Preliminary data from phase I clinical trial (NCT03874897) demonstrated that CLDN18.2-targeted CAR-T cells were safe and showed some antitumor activities in advanced gastrointestinal cancer, including pancreatic cancer [5]. Here, CLDN18 is linked to familial pancreatic carcinoma.